Alpelisib in the Spotlight: A Review of Its Efficacy and Safety in PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Abstract: Alpelisib, a selective inhibitor of the phosphatidylinositol 3-kinase (PI3K) alpha isoform, has emerged as a promising therapeutic option for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer harboring PIK3CA mutations. This review provides a comprehensive overview of the clinical efficacy and safety profile of alpelisib in the … Read more